In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STS Biopolymers Inc.

Division of Angiotech Pharmaceuticals Inc.
www.stsbiopolymers.com

Latest From STS Biopolymers Inc.

J&J's Yondelis Leads New Wave Of Sarcoma Drugs

Cardiovascular Cancer

Janssen's Yondelis gains priority review in soft tissue sarcoma

Johnson & Johnson subsidiary Janssen Research & Development was granted a priority review by the FDA for Yondelis (trabectedin) as a treatment for patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.

Cancer

CytRx touts survival data after aldoxorubicin hold lifted

CytRx has shared updates for more than a year from the Phase IIb soft tissue sarcoma (STS) clinical trial for aldoxorubicin, a modified version of the chemotherapy agent doxorubicin, but the company's stock traded flat on 22 January after CytRx reported a 1.6-month overall survival benefit in the trial.

Gastrointestinal Cardiovascular

JnJ/Janssen seek US Yondelis OK in soft tissue sarcoma

Johnson & Johnson subsidiary Janssen Research & Development is seeking the FDA's approval to market Yondelis (trabectedin), a multimodal synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata, as a treatment for patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.

Cancer Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Angiotech Pharmaceuticals Inc.
  • Senior Management
  • Richard Richmond, Pres. & CEO
    Richard Whitbourne, CTO
    John Lanzafame, Pres.
  • Contact Info
  • STS Biopolymers Inc.
    Phone: (585) 321-1130
    336 Summit Point Dr.
    Henrietta, NY 14467
    USA
UsernamePublicRestriction

Register